Literature DB >> 27229748

Percutaneous transcatheter embolisation of active haemorrhage following radiofrequency ablation of hepatocellular carcinoma.

Adam A Dmytriw1, Michael Devin Rivers-Bowerman1, Joel Woodley-Cook1.   

Abstract

A 72-year-old woman with hepatitis C virus cirrhosis underwent a surveillance ultrasound examination which identified a new hepatic lesion. A workup triphasic CT examination demonstrated a 3.7 cm lesion at the hepatic dome with arterial enhancement and portal venous washout consistent with hepatocellular carcinoma. She subsequently proceeded for treatment with radiofrequency ablation (RFA). RFA was technically successful, but the patient became hypotensive and tachycardic postprocedure. A CT angiogram demonstrated active arterial intraperitoneal haemorrhage from the RFA site. The patient returned to the interventional suite for catheter angiography which confirmed the presence of active haemorrhage from the hepatic arterial branch supplying segment VIII. The bleeding vessel was selectively catheterised with a microcatheter, and successfully embolised with 250-355 µm polyvinyl alcohol particles. 2016 BMJ Publishing Group Ltd.

Entities:  

Mesh:

Year:  2016        PMID: 27229748      PMCID: PMC4885421          DOI: 10.1136/bcr-2016-215466

Source DB:  PubMed          Journal:  BMJ Case Rep        ISSN: 1757-790X


  14 in total

1.  Multidisciplinary Canadian consensus recommendations for the management and treatment of hepatocellular carcinoma.

Authors:  M Sherman; K Burak; J Maroun; P Metrakos; J J Knox; R P Myers; M Guindi; G Porter; J R Kachura; P Rasuli; S Gill; P Ghali; P Chaudhury; J Siddiqui; D Valenti; A Weiss; R Wong
Journal:  Curr Oncol       Date:  2011-10       Impact factor: 3.677

2.  Embolization agents-which one should be used when? Part 2: small-vessel embolization.

Authors:  Michael Lubarsky; Charles Ray; Brian Funaki
Journal:  Semin Intervent Radiol       Date:  2010-03       Impact factor: 1.513

3.  Embolization agents-which one should be used when? Part 1: large-vessel embolization.

Authors:  Michael Lubarsky; Charles E Ray; Brian Funaki
Journal:  Semin Intervent Radiol       Date:  2009-12       Impact factor: 1.513

4.  Frequency of and risk factors for complications after liver radiofrequency ablation under CT fluoroscopic guidance in 1500 sessions: single-center experience.

Authors:  Haruyuki Takaki; Koichiro Yamakado; Atsuhiro Nakatsuka; Tomomi Yamada; Katsuya Shiraki; Yoshiyuki Takei; Kan Takeda
Journal:  AJR Am J Roentgenol       Date:  2013-03       Impact factor: 3.959

5.  Hepatocellular carcinoma: radio-frequency ablation of medium and large lesions.

Authors:  T Livraghi; S N Goldberg; S Lazzaroni; F Meloni; T Ierace; L Solbiati; G S Gazelle
Journal:  Radiology       Date:  2000-03       Impact factor: 11.105

6.  Radiofrequency ablation of a solitary liver metastasis complicated by colonic perforation.

Authors:  Alexander W Korutz; Kent T Sato
Journal:  Semin Intervent Radiol       Date:  2011-06       Impact factor: 1.513

7.  Major complications after radio-frequency thermal ablation of hepatic tumors: spectrum of imaging findings.

Authors:  Hyunchul Rhim; Kwon-Ha Yoon; Jeong Min Lee; Yoonkoo Cho; June-Sik Cho; Seung Hoon Kim; Won-Jae Lee; Hyo Keun Lim; Gyoung-Jin Nam; Sang-Suk Han; Yun Hwan Kim; Cheol Min Park; Pyo Nyun Kim; Jae-Young Byun
Journal:  Radiographics       Date:  2003 Jan-Feb       Impact factor: 5.333

Review 8.  The role of interventional radiology in the management of hepatocellular carcinoma.

Authors:  N Molla; N AlMenieir; E Simoneau; M Aljiffry; D Valenti; P Metrakos; L M Boucher; M Hassanain
Journal:  Curr Oncol       Date:  2014-06       Impact factor: 3.677

9.  Management of hepatocellular carcinoma: an update.

Authors:  Jordi Bruix; Morris Sherman
Journal:  Hepatology       Date:  2011-03       Impact factor: 17.425

10.  Efficacy of radiofrequency ablation of hepatocellular carcinoma associated with chronic liver disease without cirrhosis.

Authors:  Andrea Salmi; Renato Turrini; Giovanna Lanzani; Antonella Savio; Livio Anglani
Journal:  Int J Med Sci       Date:  2008-10-27       Impact factor: 3.738

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.